Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide
本研究对接受PVX-410疫苗（靶向XBP1/CD138/CS1抗原）和西他诺司他（一种组蛋白去乙酰化酶抑制剂，HDACi）联合或不联合来那度胺治疗的冒烟型多发性骨髓瘤患者进行了Ib期临床试验，并分析了接受西他诺司他治疗的冒烟型多发性骨髓瘤患者的免疫特征。
期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-025-01272-2
Cirstea, Diana; Shome, Rajib; Samur, Mehmet; Talluri, Srikanth; Connolly, Joseph J; Wright, Alexandra Jean; Duvallet, Emilie; Joyce, Amanda N R; Lively, Kathleen; Basinsky, Gina; Yee, Andrew J; Chase, Cristiana Costa; Malek, Ehsan; Niesvizky, Ruben; Richardson, Paul G; Raje, Noopur S
表观遗传
多发性骨髓瘤
XBP1
乙酰化
骨髓瘤
CD13
CD138
免疫/内分泌
